Author Archives: admin

Cord Blood Registry’s New Disease Registry Brings Data and Families Together to Advance Stem Cell Research

SAN BRUNO, CA – June 8, 2015 –Cord Blood Registry® (CBR®), the world’s largest newborn stem cell company, today announced the launch of CBR’s Family Health Registry, a unique registry designed to offer insight into common diseases and conditions affecting families and to bring patients, healthcare professionals and researchers together to expedite and facilitate research related to the discovery of stem cell treatments and potential cures.

The registry serves as an extension to CBR’s Newborn Possibilities Program®, which uses health history screening to identify families who may benefit from cord blood banking and offers free newborn stem cell processing and storage for five years to families with a qualifying medical need. To date, the Newborn Possibilities Program has enrolled more than 6,000 families, storing newborn stem cells for at-risk individuals, releasing more than 70 units for therapeutic use, and connecting patients to FDA-approved autologous cord blood clinical trials.  

Profiled health data from family respondents is already yielding valuable information. For example, based on recent survey data, although CBR’s clients are relatively young, a surprisingly high number of families

(approximately 1 in 7) have at least one indicated condition that might benefit from stem cell transplantation and/or potentially from the use of autologous or related allogeneic stem cells in regenerative medicine therapies.

“The combination of individual medical and familial information in an accessible database will empower families interested in preventing illness or reducing risk of disease. It will also help researchers develop insights that may improve outcomes and uses of novel technologies including those using stem cells,” said Paul Billings, MD, PhD, chief medical officer of Omicia, and former founder of CBR.

The most common transplant indications reported among first-degree family members were:

  • Non-Hodgkin’s Lymphoma (18.9 percent)
  • Hodgkin’s Lymphoma (17.7 percent)
  • Acute Lymphoblastic Leukemia (16.2 percent)
  • Sarcoma (8.1 percent)
  • Acute Myelogenous Leukemia (6.5 percent)
  • Sickle Cell Disease (5.7 percent)

The most common regenerative indications among children with stored umbilical cord blood were:

  • Autism/Autism Spectrum Disorder/Apraxia (37.2 percent)
  • Other Developmental Delay (26.5 percent)
  • Congenital Heart Defect (15.8 percent)
  • Childhood Hearing Loss (8.2 percent)
  • Type I Diabetes (5.3 percent)
  • Cerebral Palsy (4.9 percent)

Current trials in the U.S. are studying regenerative uses of umbilical cord blood stem cells for a wide variety of conditions including:

  • Cerebral Palsy – Approximately 8,000 to 10,000 babies born in the U.S. each year will develop cerebral palsy (Source: CerebralPalsy.org) 
  • Ischemic/Hypoxic Brain Injury – Approximately 20 out of every 1,000 full term births and 60 percent of all premature births in the U.S. are affected by Ischemic/Hypoxic Brain Injury (Source:Cerebralpalsy.org) 
  • Autism – Approximately 58,000 children are diagnosed with autism each year in the U.S. (Source: CDC) 
  • Acquired Hearing Loss – Approximately 12,000 babies born each year in the U.S. have hearing loss (Source: Boston Children’s Hospital/NIH) 
  • Hypoplastic Left Heart Syndrome – Over 900 babies in the U.S. each year are born with Hypoplastic Left Heart Syndrome (Source: CDC) 

Contact Information: 

Tina Amirkiai

FleishmanHillard

Tel: (415) 318-4262

Email: tina.amirkiai@fleishman.com

Jennifer Bruursema

Cord Blood Registry

Tel: (650) 922-6603

Email: jbruursema@cordblood.com